Introduction
============

Psoriasis is a chronic inflammatory skin disease characterized by epidermal hyperplasia, impaired epidermal differentiation, and accumulation of distinct leukocyte subpopulations \[[@b1]\]. Vascular endothelial growth factor (VEGF) was identified as a major epidermis-derived vessel-specific growth factor that was strongly up-regulated in psoriatic skin lesions \[[@b4]\]. The role of VEGF in the pathogenesis of psoriasis was further supported by studies on VEGF transgenic mice \[[@b6]\] and one modifier VEGF gene \[[@b8]\]. Therefore, VEGF may play a key causative role in mechanisms underlying the development of psoriasis \[[@b7]\].

The biological effects of VEGF are mediated by VEGF receptors (VEGFRs, including VEGFR-1 \[flt-1\], VEGFR-2 \[KDR/flk-1\], VEGFR-3 \[flt-4\]) and neuropilins (NRPs, including NRP-1and NRP-2) \[[@b10]\]. Recently, VEGFR-1 has been detected in murine keratinocytes during wound repair and in normal human epidermal keratinocytes \[[@b14]\]. We have detected that all identified VEGFRs are expressed on keratinocytes in normal human epidermis \[[@b15]\] and that VEGFR-2 is expressed on the HaCaT keratinocyte cell line \[[@b16]\] and involved in the proliferation and migration of normal keratinocytes \[[@b15]\]. It is possible that VEGFRs may play an important role in regulating psoriatic keratinocyte activity. Based on this hypothesis, we studied the expression of VEGFRs on psoriatic epidermal keratinocytes. Given the importance of VEGF in the pathogenesis of psoriasis \[[@b1]\]; the calcium gradient within the epidermis is known to be directly implicated in the homeostasis of the skin, regulating keratinocyte growth and differentiation \[[@b17]\] and; that VEGF can enhance expression of VEGFR-2 in HaCaT cells \[[@b16]\], we further investigated the interactions between calcium, VEGF and VEGFRs in non-lesional psoriatic keratinocytes.

Materials and methods
=====================

Human participants
------------------

Patients with moderate to severe active chronic plaque psoriasis (*n*= 17, including 10 females and seven males, aged 19--65) were recruited to the study from the department of Dermatology at the Second Affiliated Hospital, Zhejiang University School of Medicine. All patients gave informed written consent. During 1 month prior to biopsy, they had received no therapy for the psoriasis. Biopsies were taken from perilesional (within 2 cm from the lesion), non-lesional (at least 5 cm from the lesion) healthy-looking skin and lesional skin. Healthy age-matched participants (*n*= 11) obtained from cosmetic surgery served as controls. After removing subcutaneous elements, the specimens were divided into two parts. One part was snap frozen and embedded in optimal cutting temperature (OCT) compound (Miles, Naperville, IL, USA) and then stored in liquid nitrogen until processed. The other was placed into 0.5% dispase (Gibco, Invitrogen, USA) immediately. This study was conducted in agreement with the Declaration of Helsinki and performed under the guidelines of the institutional review committee of Zhejiang University.

Isolation and culture of epidermal keratinocytes
------------------------------------------------

Epidermal keratinocytes were cultured as described previously \[[@b15]\]. Briefly, the tissues were incubated overnight at 4°C in 0.5% dispase. The epidermis was peeled off from the dermis and incubated in 0.25% trypsin for 10 min at 37°C. The keratinocytes suspension was filtered and cells were washed twice at 500 g for 5 min prior to resuspension in defined keratinocyte serum free medium (KSFM) supplemented with keratinocyte growth factor (KGF) (Gibco, Invitrogen, USA). Normal, psoriatic non-lesional, perilesional and lesional keratinocytes were plated into 25 cm^2^ tissue culture dish respectively and maintained at 37°C in a humidified atmosphere containing 5% CO~2~. Cells were used at passages 2--3 in all experiments.

Indirect immunofluorescence assay
---------------------------------

Immunofluorescence assay was carried out as described previously \[[@b15]\]. Briefly, psoriatic and normal skin tissue specimens embedded in OCT compound were processed into 4 μm sections. Sections were placed on the surface of coverslips incubated with 1 μg/ml poly-L-lysine. After being fixed in 4% paraformaldehyde buffer for 20 min at room temperature, the coverslips were placed into preheated sodium citrate buffer (10 mM Sodium Citrate Buffer, pH 8.5), maintained at 95°C for 20 min, then incubated with 20 μg/ml of primary monoclonal antibodies diluted with 10% rabbit serum in PBS against VEGFR-1, VEGFR-3 (R&D, USA) and VEGFR-2 (Santa Cruz Biotechnology, USA) overnight at 4°C, followed by fluoresceinisothio-cyanate (FITC)-conjugated rabbit anti-mouse secondary antibody (DakoCytomation, Denmark) diluted 1:40 with 10% rabbit serum in phosphate-buffered saline (PBS) for 2 hrs at room temperature, away from light. The nuclei were counterstained with propidium iodide (PI) (Sigma-Aldrich, USA) mounting medium. For each case, a negative control incubated with non-immune mouse IgG (Sigma-Aldrich, USA) was included.

Reverse transcription and polymerase chain reaction (RT-PCR)
------------------------------------------------------------

Total RNA was isolated from cultured keratinocytes using 1ml Trizol (Invitrogen, USA) reagent according to the manufacturer\'s instructions and stored at --80°C until use. Total RNA was reverse-transcribed into first strand cDNA in a total reaction volume of 20 μl using Moloney murine leukemia virus (MMLV) reverse transcriptase (MBI Fermantas, USA). Specific primers for VEGFR-1, VEGFR-2, VEGFR-3 and VEGF were designed by using PrimerSelect program in DNAstar package (DNAStar Inc., Madison, WI, USA) ([Table 1](#tbl1){ref-type="table"}). RT-PCR amplification was performed with a PTC 225 thermal cycler (MJ Research) with 35 cycles ([Table 1](#tbl1){ref-type="table"}). In each experiment, negative control (using total RNA as the template) was included.

###### 

PCR primers used in this study

  Gene                                     GenBank accession no.   Primer sequence (5′→ 3′)                            Location              Annealing temperature (°C)   Product length (bp)
  ---------------------------------------- ----------------------- --------------------------------------------------- --------------------- ---------------------------- ---------------------
  VEGFR-1                                  NM_002019               ATGGCTCCCGAATCTATCTTTGAC GCCCCGACTCCTTACTTTTACTGG   3445-3468 4099-4076   57                           655
  VEGFR-2                                  NM_002253               CTGGCGGCACGAAATATCCTCTTA GGGCACCATTCCACCAAAAGAT     3388-3411 4164-4143   57                           777
  VEGFR-3                                  NM_182925               AGGCCGGCCCACGCAGACATC TGCACGCCCCGAGGAGGTTGA C       2424-2444 2769-2748   63                           346
  VEGF                                     NM_003376               GGAGGAGGGCAGAATCATCACGAA CACCGCCTCGGCTTGTCACAT      1125-1148 1678-1658   59                           350, 446, 482, 536
  GAPDH                                    NM_002046               TGAAGGTCGGAGTCAACGG TGGAAGATGGTGATGGGAT             113-131 335-317       57                           223
  Primers for Real-time quantitative PCR                                                                                                                                  
  VEGFR-1                                  NM_002019               AGCGGCTCCCTTATGATGC GCCGTGGCCCCCTCTTT               2681-2699 2855-2839                                175
  VEGFR-2                                  NM_002253               ATGGGAACCGGAACCTCACTATC GTCTTTTCCTGGGCACCTTCTATT    2453-2475 2585-2562   55                           133
  VEGFR-3                                  NM_182925               CAACTGGGTGTCCTTTCC CTTGTCTATGCCTGCTCTC              3713-3730 3900-3882                                188
  GAPDH                                    NM_002046               TGCACCACCAACTGCTTAG GAGGCAGGGATGATGTTC              556-574 731-714                                    186

Real time quantitative RT-PCR (qPCR)
------------------------------------

To quantitate the expression levels of the target genes, real-time quantitative RT-PCR was performed on the Roche LightCycler 2.0 (Roche Diagnostic, Germany) using Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen, USA) with primers in [Table 1](#tbl1){ref-type="table"}. The amplification protocol consisted of incubations at 95°C for 30 sec, 55°C for 30sec and 72°C for 10 sec for 50 cycles. All qPCR reactions were performed in duplicate. A no template control is included for each measurement. The expression data for each gene were normalized for the efficiency of amplification, as determined by a standard curve included in each run. The crossing point (CP) of target gene in each sample was normalized to glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) for RNA amount variation and the relative quantification was calculated using qBase version 1.3.5 \[[@b22]\].

Western blot analysis
---------------------

The method was performed as described previously \[[@b15]\]. Briefly, total cellular protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene fluoride (PVDF) membrane (Hybond-P, Amersham, USA). Blots were blocked 30 min at room temperature in PBS (pH 7.5) containing 1% Tween-20. The membrane was probed with the respective primary antibody overnight at 4°C in blocking buffer and then incubated for 1 hr with horseradish peroxidase-conjugated sheep polyclonal antimouse IgG antibody (1:5000, Jackson, USA). The reactions were detected by using ECL plus reagent kit (Amersham, USA) and exposure for 3 min to Kodak film (Kodak, USA). A mouse monoclonal anti-*GAPDH* (Acris Antibodies GmbH, Germany) was used as a loading control.

Regulation of VEGFRs by VEGF~165~ at 10 ng/ml and bevacizumab
-------------------------------------------------------------

We detected that VEGF~165~ maximally enhanced the expression of VEGFR-2 mRNA and protein at a concentration of 10 ng/ml in a keratinocyte cell line \[[@b16]\]. Therefore, 10ng/ml VEGF~165~ (Chemicon, USA) was used to determine the effect of VEGF on protein levels of VEGFRs in non-lesional psoriatic keratinocytes (*n*= 5). The targeted, neutralizing monoclonal antibody against VEGF, bevacizumab (Avastin, Genentech, USA), which is highly active in treatment of several malignancies and has been approved for use in metastatic colon cancer therapy \[[@b23]\], diluted with culture medium to obtain 1.0 mg/ml (at or above the dose normally used in clinical practice \[[@b24]\]), was co-incubated with VEGF~165~ to examine its role in VEGF-induced effect on expression of VEGFRs.

Effect of calcium on the expression of VEGFRs and VEGF in non-lesional psoriatic keratinocytes
----------------------------------------------------------------------------------------------

To determine the effect of calcium treatment on the expression of VEGFRs and VEGF, 80%∼90% confluent non-lesional psoriatic epidermal keratinocytes (*n*= 5) were incubated with calcium chloride (CaCl~2~) at concentrations of 0, 0.5, 1.0, 2.0, 3.0 mM in basal defined KSFM for 24 hrs at 37°C in 5% CO~2~. Total RNA was extracted and then reversed transcripted into cDNA. Protein was separated by SDS-PAGE (12% for VEGF, 6% for VEGFRs), respectively. To further identify whether calcium regulates expression of VEGFRs through production of VEGF, cultured non-lesion-al psoriatic keratinocytes (*n*= 3) were exposed to beva-cizumab at a concentration of 1.0 mg/ml in the presence of calcium at 1.0 mM.

Statistics
----------

Statistical significance of differences in mean values was evaluated by one-way analysis of variance ([anova]{.smallcaps}) and Student\'s t-test. A value of *P* \<0.05 was declared as significant. The levels of gene transcripts and protein were quantified as the ratio of the band intensity of the target gene to that of cor-respongding *GAPDH*. The data represent the mean ±SEM.

Results
=======

Immunofluorescence analysis of VEGFRs in non-lesional,perilesional and lesional psoriatic skin
----------------------------------------------------------------------------------------------

In normal skin, VEGFR-1 and VEGFR-2 were localized notably in the basal and suprabasal layer. In upper stratum spinosum and granulosum, few keratinocytes exhibited signals for VEGFR-1 and VEGFR-2. However, in psoriatic skin, VEGFR-1 and VEGFR-2 strongly labeled non-lesional, perilesional keratinocytes in all layers of the epidermis except the stratum corneum, and lesional keratinocytes in all viable layers, including the parakeratotic stratum corneum ([Fig. 1](#fig01){ref-type="fig"}). A uniform expression pattern of VEGFR-3 was detected in both normal and psoriatic epidermis except for stratum corneum. Interestingly, parakeratotic keratinocytes in lesional psoriatic stratum corneum also showed intense fluorescence for VEGFRs ([Fig. 1](#fig01){ref-type="fig"}). In good agreement with a previous study \[[@b5]\], papillary dermal microvascular endothelial cells (PDMECs) were also strongly stained for VEGFRs, which served as internal positive controls.

![Immunofluorescence detection of VEGFRs in normal, non-lesional, perilesional and lesional psoriatic skin. The presence of VEGFRs is indicated by green fluorescence staining. All sections were counterstained with PI (red nuclear signal). The epidermal rete ridges are elongated in psoriatic lesions. Perilesional, non-lesional psoriatic and normal skins have a thin epidermis. Only small capillaries are visible in the papillary dermis of normal skin, while psoriatic plaques contain enlarged blood vessels. VEGFR-1, VEGFR-2, VEGFR-3 accumulation was found in psoriatic epidermis. VEGFRs were also observed in the parakeratotic stratum corneum of lesional psoriatic skin (asterisk). Blood vessels were stained as internal positive control (arrow head). Negative controls that were incubated with non-immune mouse IgG show no signals in any compartment of the normal or psoriatic skin. E, epidermis;D, dermis. Bars: indicated on the photo.](jcmm0012-0649-f1){#fig01}

VEGFRs intracellular localization varied from normal to lesional psoriatic skin ([Fig. 1](#fig01){ref-type="fig"}). In normal and non-lesional psoriatic epidermal keratinocytes, VEGFRs predominantly exhibited a membranous localization, whereas in perilesional and lesional psoriatic keratinocytes, the mixed membranous and cytoplasmic localization of VEGFRs extended throughout all immunostained layers.

mRNA and protein levels of VEGFRs were overexpressed in psoriatic keratinocytes as compared to normal keratinocytes
-------------------------------------------------------------------------------------------------------------------

mRNA extracted from cultured keratinocytes in different stages of psoriatic skin from the same patient was compared. RT-PCR and qPCR demonstrated that mRNA of VEGFRs was expressed in all 17 cases of psoriasis ([Fig. 2A--C](#fig02){ref-type="fig"}). mRNA level of VEGFR-1, VEGFR-2 and VEGFR-3 were found to be gradually increased from normal to non-lesional and perilesional psoriatic keratinocytes and, the most highly increased levels of VEGFRs mRNA were observed in lesional psoriatic keratinocytes ([Fig. 2B and C](#fig02){ref-type="fig"}).

![mRNA and protein levels of VEGFRs determined by RT-PCR, qPCR and Western blot, respectively, in cultured normal and psoriatic epidermal keratinocytes. (**A**) VEGFR-1, band at 655bp; VEGFR-2, band at 777bp; VEGFR-3, band at 346bp; *GAPDH* at 223bp served as an internal control for mRNA. (**B**) Scatter plots for RT-PCR band intensity ratio of targeted VEGFR gene *versus GAPDH* using Gel-Pro Analyzer software V4.0 (Media Cybernetics, USA). Expression of VEGFRs mRNA is statistically significant different between LPK and other indicated cells (*P* \<0.001). (**C**) Relative quantitation of VEGFRs expression levels in NHEK, NLPK, PLPK and LPK by real-time RT-PCR. The expression of VEGFRs was normalized to the endogenous control *GAPDH*. The relative fold change of VEGFRs in NLPK, PLPK and LPK was compared with NHEK. The level of VEGFRs in LPK is significantly higher than that in NHEK, PLPK and LPK (*P* \<0.001). Bars: mean±SEM. (**D**) The anti--VEGFR-1, anti--VEGFR-2 and anti--VEGFR-3 antibodies show bands at about 180 and 200KD. *GAPDH* served as a loading control for protein normalization. (**E**) Scatter plot analysis of protein levels of VEGFRs *versus GAPDH* as determined by Western blot. Expression of VEGFRs protein is statistically significant different between LPK and other indicated cells (*P* \< 0.001). NHEK, normal human epidermal ker-atinocytes (*n*= 11); NLPK, non-lesional psoriatic keratinocytes (*n*= 17); PLPK, perilesional psoriatic keratinocytes (*n*= 17); LPK, lesional psoriatic keratinocytes (*n*= 17); neg, negative control.](jcmm0012-0649-f2){#fig02}

Protein level of VEGFRs was also examined in normal skin (*n*= 11) and, non-lesional, perilesional, lesional psoriatic skin (*n*= 17) from the same patient by Western blot. As shown in [Figure 2D and E](#fig02){ref-type="fig"}, a robust up-regulation of VEGFR-1, VEGFR-2 and VEGFR-3 protein was observed in lesional psoriatic skin compared to normal, non-lesional and perilesional psoriatic skin, paralleling the results obtained by RT-PCR ([Fig. 2](#fig02){ref-type="fig"}).

Calcium up-regulated expression of VEGF in non-lesional psoriatic keratinocytes *in vitro*
------------------------------------------------------------------------------------------

In non-lesional psoriatic epidermal keratinocytes, RT-PCR analysis identified the mRNA expression of four VEGF isoforms, including VEGF~121~, VEGF~145~, VEGF~165~ and VEGF~189~, corresponding to expected size at 350 bp, 446 bp, 482 bp and 536 bp respectively ([Fig. 3A](#fig03){ref-type="fig"}). Calcium-enhanced expression of VEGF~121~, VEGF~165~ and VEGF~189~ in a dose-dependent manner and maximally at 1.0 mM, while higher concentrations did not show more stimulation effect ([Fig. 3A and B](#fig03){ref-type="fig"}). Little or no difference was seen for the mRNA of VEGF~145~ after varies concentrations of calcium treatment ([Fig. 3A and B](#fig03){ref-type="fig"}). In parallel with mRNA expression, protein levels of VEGF~121~, VEGF~165~ and VEGF~189~, corresponding to 34 KD, 38 KD and 40 KD band respectively, were also peaked at a calcium concentration of 1.0 mM, especially for VEGF165 ([Fig. 3C](#fig03){ref-type="fig"}). Expression of VEGF~165~ protein was up-regulated by calcium more strongly than that of VEGF~121~ and VEGF~189~ ([Fig. 3D](#fig03){ref-type="fig"}).

![Expression of VEGF in non-lesional psoriatic keratinocytes after calcium treatment. Non-lesional psoriatic keratinocytes from five cases of psoriasis were incubated with calcium at concentrations of 0, 0.5, 1.0, 2.0 and 3.0 mM. (**A**) mRNA expression of VEGFafter calcium treatment; *GAPDH* served as an internal control.(**B**) Scatter plots for RT-PCR band intensity ratio of VEGF gene *versus GAPDH*.(**C**) Western blot results of VEGF; *GAPDH* served as a loading control for protein normalization.(**D**) Scatter plot analysis of protein level of VEGF *versus GAPDH* as determined by Western blot.](jcmm0012-0649-f3){#fig03}

Calcium up-regulated expression of VEGFRs in non-lesional psoriatic keratinocytes independent of up-regulation of VEGF *in vitro*
---------------------------------------------------------------------------------------------------------------------------------

In a dose-dependent manner, calcium regulated the expression of VEGFRs in a parabolic pattern: calcium maximally enhanced the expression of VEGFRs mRNA at a concentration of 1.0mM, whereas higher concentrations (≥ 2.0 mM) gradually restored the mRNA expression of VEGFRs to basal levels ([Fig. 4A and B](#fig04){ref-type="fig"}). In parallel with mRNA expression, protein levels of VEGFR-1 and VEGFR-3 were also peaked at a calcium concentration of 1.0 mM, while VEGFR-2 was peaked at 0.5 mM and maintained at the same level at 1.0 mM, then restored to basal levels ([Fig. 4C](#fig04){ref-type="fig"}).

![Effect of calcium and VEGF165 on expression of VEGFRs in non-lesional psoriatic keratinocytes.(**A**) Calcium regulates mRNA level of VEGFRs. Non-lesional psoriatic keratinocytes (*n*= 5) were incubated with calcium at concentrations of 0, 0.5, 1.0, 2.0 and 3.0 mM. *GAPDH* served as internal control for mRNA.(**B**) Relative quantitation of VEGFRs mRNA by real-time RT-PCR. The expression of VEGFRs was normalized to the endogenous control *GAPDH*. The relative fold change of VEGFRs in non-lesional psoriatic keratinocytes incubated with calcium was compared to that without calcium. The mRNA level of VEGFRs in NLPK treated with calcium at 1.0 mM is significantly higher than that in other indicated concentration (*P* \<0.001). Bars: mean±SEM. (**C**) Bands at 180 KD and 200 KD are detected for VEGFR-1, VEGFR-2 and VEGFR-3. *GAPDH* served as a loading control.(**D**) Effect of VEGF165 and calcium with or without bevacizumab on protein levels of VEGFRs in non-lesional psoriatic keratinocytes. Non-lesional psoriatic keratinocytes (*n*= 3) were exposed to VEGF at 10ng/ml with or without 1.0mg/ml bevacizumab, and calcium at 1.0mM with or without 1.0mg/ml bevacizumab. Bands at 180 KD and 200 KD are detected for VEGFR-1, VEGFR-2 and VEGFR-3. *GAPDH* served as a loading control.](jcmm0012-0649-f4){#fig04}

In our previous work, we have shown that at a concentration of 10 ng/ml VEGF165 maximally enhances the expression of VEGFR-2 mRNA and protein in HaCaT cells \[[@b16]\]. Our present data shows that VEGF165 at 10 ng/ml also markedly increases expression of VEGFR-1, VEGFR-2 and VEGFR-3 in non-lesional psoriatic keratinocytes ([Fig. 4D](#fig04){ref-type="fig"}). Exposure of non-lesional psoriatic keratinocytes to bevacizumab at concentration of 1.0 mg/ml moderately to mostly reduced the amount of VEGF-induced VEGFR-1, VEGFR-2 and VEGFR-3 protein synthesis ([Fig. 4D](#fig04){ref-type="fig"}). However, no relevant inhibition of overexpression of VEGFRs was seen when non-lesional psoriatic keratinocytes were treated with 1.0 mM calcium addition with 1.0 mg/ml bevacizumab ([Fig. 4D](#fig04){ref-type="fig"}).

Discussion
==========

VEGFRs are expressed in endothelial cells \[[@b4]\], but are also expressed in a variety of other cells and tissues \[[@b26]\]. Recently, VEGFRs were detected in normal human epidermal keratinocytes at both mRNA and protein levels \[[@b14]\]. Moreover, through the VEGFR-2 pathway, VEGF enhanced the proliferation and migration of keratinocytes \[[@b15]\].

The expression of VEGFR-1 and VEGFR-2 in psoriasis was noted by one previous study \[[@b5]\], which demonstrated that VEGFR-1 and VEGFR-2 were overexpressed by PDMECs in psoriasis lesional skin through in situ hybridization (ISH). Although the authors did not mention expression of VEGFR-1 and VEGFR-2 in psoriatic epidermis, we could clearly observe that the ISH signals for VEGFR-2 in their photo ([Fig. 1D](#fig01){ref-type="fig"} in ref. 5) not only strongly labeled the PDMECs, but also dispersively labeled the lesional psoriatic epidermal keratinocytes.

To elucidate whether VEGFRs are aberrantly expressed by psoriatic epidermal keratinocytes, we compared psoriatic skin samples, including non-lesional, perilesional and lesional specimens, to normal skin samples *in vivo* and *in vitro*. Immunofluorescence showed that VEGFRs were intensely and uniformly distributed in the basal, spinous and granular stratum and PDMECs in non-lesional, perilesional and lesional epidermis ([Fig. 1](#fig01){ref-type="fig"}). However, in normal epidermis, VEGFR-1 and VEGFR-2 were preferentially distributed in the basal and suprabasal stratum. Given the probable role of VEGF as an epidermal mitogen, the restriction of VEGFR-1 and VEGFR-2 expression to the basal epidermal compartment may largely limit proliferation to basal and suprabasal keratinocytes in normal skin. However, in psoriatic epidermis, VEGFR-1 and VEGFR-2 are distributed in the whole viable epidermis, which may indicate that in psoriasis, the regenerative potency is no longer limited to the basal and suprabasal keratinocytes, but expands to the whole viable epidermis, including the parakeratotic keratinocytes ([Fig. 1](#fig01){ref-type="fig"}). Moreover, it is noteworthy that no VEGFRs were detected in stratum corneum in normal, non-lesional and perilesional samples. However, in parakeratotic stratum corneum of lesional psoriatic epidermis, VEGFRs were demonstrated. It is well known that the parakeratosis (nuclei still present in the thickened cornified layer) is due to altered differentiation of keratinocytes \[[@b2]\], therefore, it is intriguing to speculate that expression of VEGFRs may correlate with keratinocyte differentiation.

In contrast to VEGFR-1 and VEGFR-2, no obvious changes were observed for the distribution pattern of VEGFR-3 between normal and psoriatic viable epidermal layers. In adult tissues, VEGFR-3 expression was detected in normal adult tissues mainly in the lymphatic endothelium \[[@b27]\]. Blocking VEGFR-3 signaling by using a soluble VEGFR-3 protein caused regression of developing lymphatic vessels by inducing apoptosis of endothelial cell \[[@b31]\]. Therefore, the roles of VEGFR-3 in the epidermis and the bioactivities of keratinocytes need to be further explored.

Consistent with these immunofluorescent findings, the enhanced expression of VEGFRs in the psoriatic keratinocytes was further displayed at the mRNA and protein levels *in vitro*. Our findings suggested a significantly increase of VEGFRs in hyperplastic lesional psoriatic keratinocytes compared with uninvolved skin from the same individuals and normal controls. The marked differences of mRNA and protein levels of VEGFRs between lesional and uninvolved psoriatic keratinocytes indicate that a close correlation may exist between VEGFRs and keratinocyte activity in psoriasis.

Calcium has been shown to regulate the proliferation of epidermal keratinocytes *in vitro*\[[@b19]\]. The rise in free calcium after an increase in extracellular calcium concentration appears to be a prerequisite for keratinocyte differentiation \[[@b19]\]. Increased calmodulin, a calcium-binding protein, levels are associated with epidermal hyperproliferation and/or with the state of differentiation \[[@b17]\]. Psoriatic plaques contain 2--3 times more calmodulin than the skin of normal controls. Adjacent uninvolved psoriatic skin also has significantly elevated calmodulin levels \[[@b17]\]. In calcium-induced dissociation of retinal pigment epithelium cells, the expression of VEGF~121~ and VEGF~165~ was up-regulated \[[@b35]\]. Calcium channel blocker benidipine suppresses expression of VEGF \[[@b36]\], which was both expressed and secreted by epidermal keratinocytes \[[@b37]\]. Several other studies have demonstrated that VEGF expression is increased in lesional psoriatic skin, and that plasma levels of circulating VEGF protein is significantly elevated in psoriatic patients \[[@b9]\] and has a significant impact in psoriasis \[[@b38]\]. Therefore, we studied the effect of calcium on expression of VEGF splice variants, and the effect of calcium and VEGF~165~ on the expression of VEGFRs in the non-lesional psoriatic keratinocytes, which have important cellular or genetic differences with skin of normal individuals \[[@b3]\], to investigate the possible contributors for over-expression of VEGFRs in psoriasis.

Exogenous calcium up-regulated the mRNA and protein levels of VEGFRs in a dose-dependent manner and peaked at concentrations of 0.5∼1.0 mM in non-lesional psoriatic keratinocytes ([Fig. 4](#fig04){ref-type="fig"}). Furthermore, calcium also enhanced mRNA and protein of VEGF~121~, VEGF~189~ and especially, VEGF~165~ in a dose-dependent manner and peaked at 1.0 mM. Therefore, it is appealing to conclude that calcium blockers may be effective in the therapy of psoriasis, although the calcium blockers did not decrease the concentrations of VEGF and its receptor VEGFR-1 in systemic sclerosis, a VEGF/VEGFR axis defective disease \[[@b38]\]. Further investigations should be done to confirm this.

We simultaneously determined the protein levels of VEGFRs in non-lesional psoriatic keratinocytes after being stimulated by VEGF165 at a concentration of 10 ng/ml, which enhanced the protein levels of VEGFR-1, VEGFR-2 and VEGFR-3. Since exogenous VEGF could significantly enhance expression of VEGFRs *in vitro*, a relative abundance of VEGF present in lesional psoriatic skin might increase expression of VEGFRs *in vivo*.

Both calcium and VEGF could upregulate expression of VEGFRs, and calcium also could up-regulate the expression of VEGF. So, is it reasonable that, calcium-enhanced expression of VEGFRs indirectly through enhanced expression of VEGF?

To test this hypothesis, a targeted, recombinant humanized neutralizing monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human VEGF in *in vitro* and *in vivo* assay systems \[[@b39]\], bevacizumab, was included in the study. Bevacizumab alleviated VEGF-induced up-regulation of VEGFRs moderately to mostly. However, it did not inhibit calcium-induced overexpression of VEGFRs in cultured non-lesional psoriatic keratinocytes. Based on these results we draw two conclusions:(*i*) calcium enhances expression of VEGFRs completely independent of VEGF and;(*ii*) the concentration of calcium-induced VEGF is not enough to up-regulate expression of VEGFRs, that is, calcium enhances expression of VEGFRs mainly independent of VEGF. However, the precise mechanism of calcium- and VEGF-enhanced expression of VEGFRs is still unknown. An autocrine loop formed by VEGF and its receptors may have an impact on the regulation of keratinocyte survival in psoriasis.

In summary, this study demonstrates overexpres-sion of VEGFR-1, VEGFR-2 and VEGFR-3 in psoriatic epidermis *in vivo* and *in vitro*. We also demonstrate that both exogenous VEGF165 and calcium can enhance expression of VEGFRs in non-lesional psoriatic keratinocytes. Although calcium also upregulate expression of VEGF isoforms including VEGF~165~ at mRNA and protein levels, blockade of VEGF activity can not inhibit calcium-induced up-regulation of protein levels of VEGFRs. Therefore, calcium may enhance expression of VEGFRs independent of VEGF. The additional efforts in VEGF/VEGFRs research will certainly provide invaluable clues to facilitate the development of novel molecular targets for the treatment of psoriasis \[[@b38]\] and their associated biological markers for predicting response. Monoclonal antibodies against VEGFRs may attenuate the development and maintenance of psoriatic lesion.
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